Weak hands have been shaken loose. Consolidation/accumulation by longs is coming to an end and Titan is prepped for launch. Another news cycles starts soon...

I think that gypsy sold me a broken Magic 8ball...and my tinfoil hat theories never really work out...I guess I'm stuck hoping that SPORT's best-in-class ergonomics, mobility, affordability, minimal invasiviness, etc. will somehow translate into a couple sales in a massively underserved, high-growth global industry.....

And if it doesn't play out like that, it's only because my prediction was so eerily accurate that it spooked the traders in China, who also participate on this board, and they shifted their strategy...lol...I have my theory on Longtai and McNally, but you need a tinfoil hat for it to make sense ha...

I think share price continues to decline on high volume today, with a close around .315. Tomorrow morning we see an early dip with support at .30 before a sharp recovery on high volume in the late afternoon. News on Friday morning with a close mid 40s. Break .50 on second news release Mon/Tues with continued run up to .60. Then we start this process all over with support in the mid. 40s in a couple weeks...so says my Magic 8ball.....GLTA longs

I wholeheartedly agree. I didn't mean to suggest naivety amongst the long term members of this board or Doctors; quite the opposite. I was trying to convey the idea that being a surgeon with an understanding of SPORT's potential well in advance of the greater investing public can sometimes be a curse. The hope is that the company has a leadership team that effectively markets the product's potential to the investing public, but sometimes the 'discovery' leadership team isn't as proficient at the ' development/marketing' phase.
A Doctor that discovers new technology is most likely 'brilliant.' There is going to be a tendency to be over confident in their ability to do anything academic, which is probably how they view the development process; a problem with a solution. But there are a lot of brilliant people competing in the financial market and it is wrought with nuance that is best learned through experience. A pair of genius twins graduate Harvard undergrad with double majors in pre-med and econ. One goes to Med School and then spends 20 years researching cancer, the other gets his MBA and spends 20 years at a private equity firm; Which one do you want running the development phase?? It's a credit to their brilliance that some doctors get as far as they do in the development/financing/regulatory stages. I'm not trying to criticize doctors but rather am applauding Titan's pivot toward leadership with a successful track record in the development stage. McNally is the guy.

And for the record, every biotech that I've bought into waaaaay too early has ended up making multiples for the long suffering early investor as long as the trial results lived up to the early hype. But not as much as the investor who buys right as the company transitions to a business savvy mgmt.

I've learned this the hard way and had my heart, and investment account, broken by a 5 year relationship with a cancer biotech. I sold after one final, huge failure that was the last remnant of the founding mgmt. Nothing in the narrative changed, just a sh*tty, excessively aggressive trial design. But I sold at the TITXF equivalent of .10. I couldn't watch anymore. I should have been doubling down. As new mgmt righted the ship over the next couple years, the drug reached the market and the share price increased 2000%+. Even as a 'long sufferer,' I would have made 700% over 7 years if I had just held my position through the pain. Much more if I had added at the basement. But emotions won. Not this time. Holding Titan until the story changes or SPORT fulfills it's potential. GLTA.

For the most part, Doctors are like every other profession in that there are some good, some bad, and everything in between. Although I do think you find more altruistic people in the medical profession; same as firemen, service members, teachers, etc. They also tend to be very intelligent for obvious reasons.

One of the biggest problems I've found with 'Doctor led' medical start-ups is that they develop a sort of tunnel-vision. Discovery/Invention of a new drug or technology that can advance patient care is a herculean task in and of itself, so it's understandable why the founders become so obsessive during development and as they try to bring the product to market. But the problem with being the smartest guy in the room is that all the investors, regulatory agencies, and customers may not fully grasp your vision. You have to sell the vision and play the game.

It's kind of the same reason why the Porsche some might buy after SPORT 510(k) approval won't be sold by the Engineer out of the design shop. It's going to be sold at a dealership by a salesman. Too often Doctors assume that investors/FDA/etc should 'just get it,' understand the potential patient care advancement, and throw their full support behind the product's development to market. But right or wrong, that's just not how it works in reality. The vast majority of companies with truly beneficial compounds/tech eventually bring on a management team familiar with the financial/regulatory/marketing side. I think the team that developed SPORT did a great job with the tech, albeit at the expense of long term investors. Now that there is a business savvy leader, I think Titan will make it to market and reward investors no matter where they purchased along the way. (although you'll be super happy if you bought at .10!)

Exactly lol. Recent Conversation with Mrs. Titan (whom is not particularly familiar with finances):
Her: Wait, you have how much in this company?? And it's a what, 'pink slip'? Hey, is that the stuff from Wolf of Wall Street?!?!
Me: $. 'Pink Sheet.' And yeah, but it's like Steve Madden, not all the bad ones.
Her: I hope you know what the f**k you're doing...<exits room>

I just hope McNally knows 'what the f**k' he's doing! So far so good IMHO Better than good

I have a gut feeling that we continue to see a steady decline in share price on large volume thru Thursday, with profit taking by short-term traders & and accumulation by long term investors familiar with the Titan story. I think we bottom out Thursday morning, then see a spike in volume and share price Thursday afternoon, followed by another positive news cycle starting Friday morning with a subsequent positive release Monday or Tuesday.

Most of my investment experience is with early phase Biotechs (this is my first medical device company) and I have a kind of tin-foil hat theory based on empirical evidence; Once a long suffering start-up finally turns the corner towards realizing their potential, they tend to settle into a predictable news cycle and share price pattern (similar to recent TITXF activity). I like to believe that this is management's 'wink' to long-time investors/sufferers whom have closely followed the story and an opportunity to maximize their profits on the way up. Or maybe it's just the nature of the beast that short term traders take short term profits after news and long term investors use the opportunity to shore up their position. But I think management tries to make it predictable for people that invest both their money and time

The narrative hasn't changed. I'm comfortable with my current position and it's probably irresponsible for a pink sheet stock to be as big a percent of my portfolio as it is...But I'll break my promise to myself and buy if it continues to decline until Thurs morning...sigh...

BTFD!

Could it be Installation in France? Seems due...

The Titan Website updated the 'Corporate Presentation' sometime in the last month and it speculates that the available market for the Sport system is about 12 Billion in system sales and 3.5 Billion in annual Procedure and Service Revenue. If Titan can secure 10% of the available market, that's 1.2 Billion in system sales and 350 million in annual revenue. I imagine that Titan would be happy to hit those numbers 5 years after FDA approval. So that's a mature commercialization resulting in approx 450million in annual revenue. Using Intuitive's current ratio of market cap to revenue, assume 500 million outstanding shares for 2024 Titan, and you have a potential 2024 Titan market cap of 6.75 Billion and a share price of 13.50.

If Titan uplists and institutional investors believe in the Titan story and the potential earnings, then I bet Titan hits a market cap of 300-400 upon FDA submission, 600-800 upon approval, and surpasses 1 Billion upon successful commercial launch with limited sales. I'm using Transenterix and Mazor as a rough basis for those multiples. So depending on how many outstanding shares, I would guess those market caps translate into $1+ after submission (Q3-2018), $2+ after approval(Q2-2019), $3+ after initial sales(Q4-2019).

This assessment is based on Titan hitting every milestone,successful financing, Sport living up to early reviews, wild speculation, questionable math and half-baked assumptions on my behalf. I have always believed in Titan tech and think McNally is the business savvy savior the company needed. I am holding until the story plays out or the narrative changes.(For the record, my wild guess is Titan is acquired prior to commercialization, after FDA approval, for about 2 Billion.)

You are correct, was AllorNothing. Thanks for the advice, it's been awhile since I traded a pink sheet stock. Looks like .25 is definitely not getting filled at this rate!
On another topic, I would like to thank the regular posters on the board for their continued insight in to Titan Medical and the broader robotic surgery field. I was told about Titan a couple years ago by a friend in the medical sales industry whom works closely with a myriad of surgeons. They apparently have nothing but praise for Titan's technology and are eager to see it hit the market. I was fortunate to have been on the sidelines for the prior management troubles, but I think they have the right man at the helm in McNally to navigate this next phase. I don't think Titan is totally out of the woods yet, but it sure seems like there is a lot of daylight up around the corner. The prior team seems to have done a great job with the technology, now they need a market savvy CEO to take them down the home stretch to FDA approval. I believe McNally is the man! Anyhow, thanks for all the regular insight and information!

My Bid at .25 was passed over on the way down and the way back up. Not enough volume to fill it all at once is my impression(and was only 10k shares). Interesting to see TRCX drop, while Mazor currently has a nice little pop. Agree there seems to be consolidation at this level and is a good opportunity to increase position, IMHO. I'm not excited by the inevitable R/S, but I think the advantage of being on a major exchange will far exceed the negative R/S impact, especially if the move is supported by a steady flow of positive news. Need more volume! GLTA

Yes, it seems very stagnant. I just noticed the Titan website didn't have the press release posted anymore, so I was wondering if there was updated info...but I probably shouldn't read into every minute detail....

Is there any recent news regarding the Columbia site?